NCT01273779暂停2 期
OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 发起方
- Agennix
- 入组人数
- 1,280
- 试验地点
- 99
- 主要终点
- All Cause Mortality
研究概览
简要总结
Study will evaluate the safety and potential benefit of talactoferrin (recombinant human lactoferrin) as an addition to the standard care for severe sepsis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18 years
- •Onset of severe sepsis within the previous 24 hours
- •Must be receiving antibiotic therapy
- •Informed consent form signed by patient or authorized representatives according to local rules or regulations
- •Able to take liquid medication by mouth or feeding tube
排除标准
- •Receipt of investigational medication within 4 weeks prior to participation in the study
- •Pregnant or breast-feeding
- •Severe congestive heart failure
- •Known severe HIV infection
- •Presence of severe burns
- •Patients on high dose immunosuppressants
- •Patients whose death is considered imminent
- •Patients whose life expectancy for concurrent illness is less than 6 months
- •Severe hypoxic encephalopathy or persistent vegetative state
- •Severe liver disease
- •Chronically bed bound
- •Patient, legal representative or patient's primary physician not committed to providing full, aggressive life support
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Talactoferrin alfa
Experimental
干预措施: Talactoferrin alfa (Drug)
结局指标
主要结局
All Cause Mortality
时间窗: 28 Days
次要结局
- All Cause Mortality(12 months)
- Assess Safety and Tolerability(28 days)
研究者
研究点 (99)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe SepsisSevere SepsisNCT00630656Agennix190
Unknown
3 期
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult PatientsDiarrheaNCT01382199Ventria Bioscience340
已完成
3 期
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00854035Ono Pharmaceutical Co. Ltd266
已完成
3 期
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerBreast CancerNCT02019277Hoffmann-La Roche50
终止
1 期
Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal MetastasisPeritoneal MetastasesNCT05431907Enlivex Therapeutics RDO Ltd.9